Answers are grounded in this paper and cite their sources.
Highlights that composite data from large trials may mask significant individual variability in the efficacy and safety of antiplatelet drugs.
he efficacy of various antiplatelet agents in preventing cardiovascular and thrombotic complications has been established in large-scale clinical trials. Composite data from such studies tend to mask individual variability in responsiveness to the drugs being investigated. In fact, antiplatelet drugs that are effective and safe in one individual may be ineffective or harmful in another.
No takes yet. Share an insight, caveat, or question.
Andrew I. Schafer (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: